Pharmaceutical ETFs may be in trouble with legal troubles looming over the industry. The drugmaker segment recently sold-off after an amended civil antitrust complaint brought by more than 40 state attorneys general alleged that 15 individuals and 20 corporate defendants conspired to fix prices on...